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DOTS a double-edged sword in TB 
management
Hoek et al.1 underscore the problematic role of directly 
observed treatment, short-course (DOTS) as currently practised 
in the development of tuberculosis (TB) drug resistance in 
South Africa. In terms of the current SA National TB Control 
Programme guideline, DOTS is initiated on newly diagnosed 
TB based on sputum smear microscopy and/or culture. 
The patient is put on four first-line drugs: isoniazid (INH), 
rifampicin (RIF), pyrazinamide (PZA) and ethambutol (EMB), 
for a specified period until sputum conversion, treatment 
failure or relapse intervenes. This treatment is initiated without 
prior drug sensitivity testing (DST), and is predicated on the 
assumption that all newly diagnosed cases are susceptible to 
these first-line drugs. 
However, there is good evidence that in the South African 
setting many new TB cases arise from infection with multidrug-
resistant organisms (MDR-TB) and are therefore already 
resistant to INH and RIF. The resulting under-treatment with 
the only two effective drugs in the regimen – PZA and EMB – 
sets the stage for developing resistance to both these drugs. If, 
as usually happens, PZA and ETH are subsequently included 
in the second-line regimen to manage first-line failures or 
MDR-TB, the chances of developing further resistance to the 
other second-line drugs such as streptomycin (SM) are greatly 
magnified. As a consequence of this line of management, the 
resulting MDR-TB is liable to include resistance to PZA and 
EMB as well as SM. The bottom line is that although EMB and 
PZA may be included in the treatment of MDR-TB, neither 
one should be counted as one of the four effective drugs in the 
second-line regimen, not least because resistance to PZA and 
EMB is difficult to detect on routine cultures. South African 
guidelines are being revised accordingly.
The ICT Malaria Pf card test is reliable 
for use in primary care settings
Moonasar et al.2 conducted a field evaluation in Limpopo 
province to determine the accuracy of the malaria rapid 
diagnostic test (MRDT) in use in the province’s public 
sector clinics and hospitals. Specifically, they sought to 
test the diagnostic efficacy of the ICT Malaria Pf card test, 
manufactured in Australia and widely used in South Africa. 
The test works by detecting the target antigen in the blood of 
the patient, known as ‘histidine-rich protein II’, which is found 
only in the Plasmodium falciparum mosquito. To determine the 
specificity and sensitivity of the test, they compared its results 
with those of blood smear microscopy, considered to be the 
diagnostic gold standard for malaria. The ICT Malaria Pf card 
test was found to be a highly effective diagnostic tool, with a 
sensitivity of 99.48% and a specificity of 96.26%, and amply 
meets the criteria set by the World Health Organization.
Snakebite antivenom can cause severe 
adverse effects
We publish this prospective study by Wood, Webb and 
DeMeyer3 on the management of severe snakebites in northern 
KwaZulu-Natal as evidence of the high quality of care that 
can be achieved by dedicated practitioners in outlying non-
academic settings, and as a demonstration of how meticulous 
documentation in these settings can add up to useful research. 
This study presents the snakebite management experience at 
Ngwelezane Hospital, located in largely rural north-western 
KZN, and provides a useful model of how this condition 
can best be managed in resource-constrained locations. KZN 
and Mpumalanga have the highest incidence of snakebites in 
South Africa, at 24 - 34 victims per 100 000 people. The most 
commonly reported serious cases result from envenomation 
by the Mozambique spitting cobra and the puff adder. Less 
than 10% of snakes in southern Africa are poisonous, and 
these include the Egyptian cobra, black and green mamba, 
boomslang and vine snake.
Snakebite complications include rapid progressive 
swelling, compartment syndrome, haematological disorder 
(thrombocytopenia) and neurotoxicity. The administration of 
polyvalent antivenom is indicated in the event of progressive 
complications. But it should be kept in mind that the 
antivenom can also provoke adverse reactions ranging from 
an allergic reaction (pruritus, urticaria) to anaphylactic shock 
(hypotension, bronchospasm). Antihistamine, hydrocortisone 
and adrenaline are often administered beforehand as 
prophylaxis based on theoretical considerations rather than 
empirically proven effectiveness. Antivenom is dosed the same 
for children as for adults, based on the type of snakebite and 
the amount of venom injected. It is administered intravenously 
over 10 minutes in diluted form, and titrated against 
progression in the clinical condition. Snakebite treatment may 
eventually include fasciotomy or amputation for deteriorating 
compartment syndrome.
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